$RYTM News

Rhythm Pharmaceuticals: Building A Defensive MC4R Franchise

Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday?

JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $146

Citigroup Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143

RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $155

Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $160

Rhythm Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2026 Earnings Call Transcript

Full Transcript: Rhythm Pharmaceuticals Q2 2026 Earnings Call

Rhythm Pharmaceuticals Q2 EPS $(0.73) Beats $(0.82) Estimate, Sales $71.255M Beat $67.277M Estimate

Rhythm Pharmaceuticals Announces Preliminary Results From Ongoing Phase 2 Trial Evaluating RM-718 In Patients With Acquired Hypothalamic Obesity; BMI Reductions Consistent With Setmelanotide And Bivamelagon; Sees -11.6% Mean Reduction In BMI From Baseline At Week

JP Morgan Initiates Coverage On Rhythm Pharmaceuticals with Overweight Rating, Announces Price Target of $145

Rhythm Pharmaceuticals Announces That Results From Its Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide, A Melanocortin-4 Receptor Agonist, In Patients With Acquired Hypothalamic Obesity Have Been Published In The New England Journal Of Medicine

RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $141

Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results?

Can Rhythm Pharmaceuticals (RYTM) ’s New Data Help Patients With a Rare Hunger Disorder?

Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Positive Interim Results from Phase 2 Setmelanotide Trial in Prader-Willi Syndrome - Slideshow

Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Positive Interim Results from Phase 2 Setmelanotide Trial in Prader-Willi Syndrome Transcript

Rhythm Pharmaceuticals posts long-term setmelanotide data for obesity

Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $151